FORTUNATO, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 1.246
AS - Asia 1.007
EU - Europa 691
SA - Sud America 297
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 3.276
Nazione #
US - Stati Uniti d'America 1.208
SG - Singapore 478
IT - Italia 337
BR - Brasile 229
VN - Vietnam 161
CN - Cina 144
IN - India 97
EE - Estonia 85
DE - Germania 81
HK - Hong Kong 54
FI - Finlandia 45
AR - Argentina 37
GB - Regno Unito 30
RU - Federazione Russa 20
NL - Olanda 19
SE - Svezia 18
MX - Messico 17
ZA - Sudafrica 15
CA - Canada 14
ID - Indonesia 14
EC - Ecuador 13
PK - Pakistan 11
AT - Austria 10
BD - Bangladesh 10
JP - Giappone 9
FR - Francia 8
CO - Colombia 7
IQ - Iraq 7
CZ - Repubblica Ceca 6
ES - Italia 6
PL - Polonia 6
MA - Marocco 4
TN - Tunisia 4
DO - Repubblica Dominicana 3
KE - Kenya 3
PE - Perù 3
UA - Ucraina 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BG - Bulgaria 2
CH - Svizzera 2
JO - Giordania 2
LT - Lituania 2
NI - Nicaragua 2
PS - Palestinian Territory 2
PT - Portogallo 2
RS - Serbia 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
VE - Venezuela 2
AL - Albania 1
AO - Angola 1
AU - Australia 1
BE - Belgio 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CL - Cile 1
DK - Danimarca 1
EG - Egitto 1
ET - Etiopia 1
GR - Grecia 1
HU - Ungheria 1
IE - Irlanda 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MD - Moldavia 1
PA - Panama 1
PY - Paraguay 1
QA - Qatar 1
RW - Ruanda 1
TH - Thailandia 1
TR - Turchia 1
TT - Trinidad e Tobago 1
TV - Tuvalu 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.276
Città #
Dallas 407
Singapore 241
San Jose 112
Ashburn 105
Santa Clara 97
Bengaluru 76
Chandler 66
Hefei 64
Munich 59
Ho Chi Minh City 56
Hong Kong 52
Hanoi 41
Beijing 33
Milan 33
Rome 31
Turku 30
Boardman 23
Chicago 21
São Paulo 20
Lawrence 19
London 19
Princeton 19
Helsinki 15
Wilmington 12
New York 11
Brooklyn 10
Da Nang 10
Genoa 10
San Francisco 10
Secaucus 10
Catanzaro 9
Los Angeles 9
Reggio Calabria 9
Johannesburg 8
Mexico City 7
Mingora 7
Naples 7
Pasadena 7
Piacenza 7
San Nicola Manfredi 7
Chennai 6
Rimini 6
Settingiano 6
Stockholm 6
Warsaw 6
Boston 5
Brasília 5
Buffalo 5
Haiphong 5
Lamezia Terme 5
Montreal 5
Olomouc 5
Rio de Janeiro 5
Seattle 5
Tokyo 5
Valmadrera 5
Assago 4
Aversa 4
Bari 4
Belo Horizonte 4
Biên Hòa 4
Can Tho 4
Carrara 4
Curitiba 4
Falerna 4
Guayaquil 4
Huế 4
Pune 4
Quito 4
Taranto 4
Verona 4
Alessandria 3
Amsterdam 3
Bogotá 3
Cabo Frio 3
Cape Town 3
Caxias do Sul 3
Como 3
Crotone 3
Elk Grove Village 3
Hanover 3
Joinville 3
Kemerovo 3
Lima 3
Locri 3
Maceió 3
Marano Marchesato 3
Nairobi 3
New Delhi 3
Ninh Bình 3
Novara 3
Orem 3
Palermo 3
Porto Alegre 3
Posadas 3
Redmond 3
Santo Domingo 3
The Dalles 3
Thái Nguyên 3
Arame 2
Totale 2.020
Nome #
Predictive factors of Status Epilepticus and its recurrence in patients with adult–onset seizures: A multicenter, long follow–up cohort study 138
Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy 129
Efficacy of rehabilitative techniques in reducing hemiplegic shoulder pain in stroke: systematic review and meta-analysis 91
Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST) 80
Effectiveness of perampanel as only concomitant antiseizure medication for highly active epilepsy: insight from a real-world, multicenter retrospective study 71
Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab 68
Efficacy of Virtual Reality and Exergaming in Improving Balance in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis 67
Glucose transporter-1 deficiency syndrome with extreme phenotypic variability in a five-generation family carrying a novel SLC2A1 variant 65
Adjunctive cenobamate in people with focal onset seizures: Insights from the Italian Expanded Access Program 64
A real-world comparison among third-generation antiseizure medications: Results from the COMPARE study 60
Perampanel as first add-on choice on the treatment of mesial temporal lobe epilepsy: an observational real-life study 60
Pain Management and Rehabilitation for Central Sensitization in Temporomandibular Disorders: A Comprehensive Review 59
Circulating microrna: The potential novel diagnostic biomarkers to predict drug resistance in temporal lobe epilepsy, a pilot study 59
Effectiveness and Safety of Adjunctive Cenobamate in People with Focal-Onset Epilepsy: Evidence from the First Interim Analysis of the BLESS Study 57
Phenotypic Variability in Novel Doublecortin Gene Variants Associated with Subcortical Band Heterotopia 57
Facemask headache: a new nosographic entity among healthcare providers in COVID-19 era 57
Adjunctive Brivaracetam in People with Epilepsy and Intellectual Disability: Evidence from the BRIVAracetam Add-On First Italian netwoRk Study 54
Idiopathic generalized epilepsy in a family with SCN4A-related myotonia 54
Climate change and hyponatremia-related hospital admissions in people with focal epilepsy exposed to carbamazepine or its derivatives 51
Exome sequencing of 20,979 individuals with epilepsy reveals shared and distinct ultra-rare genetic risk across disorder subtypes 50
Brand-to-Generic Levetiracetam Switching: a four-years prospective observational real-life study 50
A familial t(4;8) translocation segregates with epilepsy and migraine with aura 50
The impact of one-year COVID-19 containment measures in patients with mesial temporal lobe epilepsy: A longitudinal survey-based study 50
Effectiveness of perampanel as the only add‐on: Retrospective, multicenter, observational real‐life study on epilepsy patients 49
Neuromuscular Impairment of Knee Stabilizer Muscles in a COVID-19 Cluster of Female Volleyball Players: Which Role for Rehabilitation in the Post-COVID-19 Return-to-Play? 49
Distinguishing seizures in autoimmune limbic encephalitis from mesial temporal lobe epilepsy with hippocampal sclerosis: Clues of a temporal plus network 48
Adjunctive brivaracetam and sustained seizure frequency reduction in very active focal epilepsy 48
National survey on the prevalence of single-gene aetiologies for genetic developmental and epileptic encephalopathies in Italy 47
Novel KCNQ2 Variants Related to a Variable Phenotypic Spectrum Ranging from Epilepsy with Auditory Features to Severe Developmental and Epileptic Encephalopathies 45
Serum MicroRNAs as Predictors of Diagnosis and Drug-resistance in Temporal Lobe Epilepsy: A Preliminary Study 43
Phenotypic traits and family history in patients with 22q11.2 deletion syndrome and generalized epilepsy: A multicenter case-control study 42
Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures 42
Perampanel in post-stroke epilepsy: Clinical practice data from the PERampanel as Only Concomitant antiseizure medication (PEROC) study 42
Functional activity changes in memory and emotional systems of healthy subjects with déjà vu. 42
Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST) 41
Orbito-frontal thinning together with a somatoform dissociation might be the fingerprint of PNES 41
Ultrasound-Guided Injections and Proprioceptive Neuromuscular Facilitation as Shoulder Rehabilitation for Multiple Sclerosis and Neuropathic Pain 40
May anti‐seizure medications alter brain structure in temporal lobe epilepsy? A prospective study 40
Temporomandibular disorders and neck pain in primary headache patients: a retrospective machine learning study 40
Exploring the Effectiveness of Adjunctive Cenobamate in Focal Epilepsy: A Time-Based Analysis 40
Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study 39
Epilepsy, Immunity and Neuropsychiatric Disorders 39
Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST) (CNS Drugs, (2021), 35, 12, (1289-1301), 10.1007/s40263-021-00856-3) 39
Non-Coding RNAs: New Biomarkers and Therapeutic Targets for Temporal Lobe Epilepsy 38
Epileptic belly dancing: a video-polygraphic recording 38
Personality disorders in individuals with functional seizures: a systematic review 37
Patterns of subregional cerebellar atrophy across epilepsy syndromes: An ENIGMA‐Epilepsy study 37
The spectrum of epilepsy with eyelid myoclonia: delineation of disease subtypes from a large multicenter study 37
Neuropsychiatric profile in average intelligent individuals with coexisting epilepsy and psychogenic non-epileptic seizures 37
Late drug-resistance in mild MTLE: Can it be influenced by preexisting white matter alterations? 37
Focal neuromyotonia associated with a C9ORF72 expansion mutation 37
Topiramate ban in women of childbearing potential with idiopathic generalized epilepsy: Does effectiveness offset the teratogenic risks? 36
Focal epilepsy with sensory seizures associated with arginine:glycine amidinotransferase deficiency: A clinical and advanced magnetic resonance imaging study 35
Tremor as an intrinsic feature of juvenile myoclonic epilepsy 35
Lamotrigine vs levetiracetam in female patients of childbearing age with juvenile absence epilepsy: A Bayesian reanalysis 35
Genome-wide association meta-analyses of drug-resistant epilepsy 34
Neuroma of the Inferior Alveolar Nerve: A Treatable Mimic of Refractory Trigeminal Neuralgia 34
Electroclinical Features and Long-term Seizure Outcome in Patients With Eyelid Myoclonia With Absences 33
null 33
Two Novel Variants in the CHRNA2 and SCN2A Genes in Italian Patients with Febrile Seizures 32
Second-Line Medications for Women Aged 10 to 50 Years with Idiopathic Generalized Epilepsy 31
Climate change and disorders of the nervous system 30
Effects of intensive rehabilitation on functioning in patients with mild and moderate Charcot–Marie-Tooth disease: a real-practice retrospective study 30
Hereditary Spastic Paraplegia Associated with Ultra-Rare Variant Enrichment Encompassing the SYNE1, CAPN1 and PGAP1 Genes 29
Late-Onset Ictal Asystole and Falls Related to Severe Coronary Artery Stenosis: A Case Report 28
Exosomes from Human Periapical Cyst-MSCs: Theranostic Application in Parkinson's Disease 26
Brand-to-generic levetiracetam switching: a 4-year prospective observational real-life study 26
Epilepsy with generalized tonic–clonic seizures alone: Electroclinical features and prognostic patterns 26
GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture 25
Babylonian knowledge about temporal lobe epilepsy: distinguishing mesial from lateral forms 24
PAK3 pathogenic variant associated with sleep-related hypermotor epilepsy in a family with parental mosaicism 24
Predictors of Seizure Recurrence in Women With Idiopathic Generalized Epilepsy Who Switch From Valproate to Another Medication 22
Event-based modeling in temporal lobe epilepsy demonstrates progressive atrophy from cross-sectional data 20
Sex-based electroclinical differences and prognostic factors in epilepsy with eyelid myoclonia 17
Lacosamide is Associated with a Higher Treatment Persistence at 12 Months than Brivaracetam and Perampanel Despite Similar Efficacy 13
National survey on the prevalence of single-gene aetiologies for genetic developmental and epileptic encephalopathies in Italy 12
Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST) 6
Response: Letter to the Editor – Climate, hyponatremia, and epilepsy: A critical signal demanding broader scrutiny 3
Totale 3.394
Categoria #
all - tutte 22.264
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.264


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202126 0 0 0 0 0 0 2 5 9 9 1 0
2021/202288 0 0 0 10 7 14 5 15 16 8 11 2
2022/2023241 44 24 20 40 18 20 2 14 22 7 19 11
2023/2024190 27 30 13 14 19 22 17 14 6 4 6 18
2024/2025989 53 21 23 78 80 122 78 44 78 103 103 206
2025/20261.849 140 212 510 481 254 114 138 0 0 0 0 0
Totale 3.394